International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 5, Issue 1, pp: (231-238), Month: April - September 2017, Available at: www.researchpublish.com

Comprehensive Review of Heart Failure

[1]Abdulrahman Humied Alotaibi, [2]Abdulrahman Abdullah Alzahrani, [3]Faisal Adel Alsuqati, [4]Ahmed Mohammed Althubaiti, [5]Ahmed Faisal Siraj, [6]Torky Ahmed Arab, [7]Ahmed Mohammed Althubaiti, [8]Mohammed Abdulaziz Kattan, [9]Atheer Abdulrahman Ghous

Abstract: **This review was aimed to focuses on the main principles of heart failure, causes, consequences, mortality, symptoms, and diagnosis of HF. We attempted to also review the incidence of HF worldwide as well as the classification of HF. Comprehensive literature review was conducted using MEDLINE, CINAHL, PubMed, PsycINFO, and Cochrane Library to identify publications Up to May,2017. Method used several Keywords as; "heart failure" "Classification" "diagnosis" "Mortality". We restricted our search to only English published articles with human subjects. HF is, and will continue to be, a substantial problem on health-care systems and societies. Although age-adjusted occurrence has actually typically not been discovered to have actually increased recently, the occurrence of HF will likely continue to increase offered the significant aging of the population, enhanced survival with HF. The diagnosis of HF requires careful evaluation of each patient. Diagnostic screening is extremely influenced by the quality of the preliminary assessment and the recognition of comorbid conditions. Classifying a patient's cardiomyopathy will assist guide treatment and lend prognostic value as new and standard treatments are used.**

Keywords: **Heart failure (HF), heart problems, Cardiovascular Health Study (CHS).**

1. INTRODUCTION

Heart failure (HF) is a complicated professional syndrome caused by architectural or useful heart problems that impair the capability of one or both ventricles to fill with or expel blood [(1)]. HF is a significant public health problem with an existing prevalence of over 5.8 million in the USA as well as over 23 million worldwide [(2,3)]. Every year in the USA, more than 550,000 people are identified with HF for the very first time, and there is a life time risk of one in 5 of creating this syndrome [(2,4)]. A diagnosis of HF brings considerable risk of morbidity and mortality, despite advances in monitoring. Over 2.4 million patients that are hospitalized have HF as a primary or secondary diagnosis, as well as almost 300,000 deaths each year are directly attributable to HF [(2)].

HF is the final usual stage of numerous diseases of the heart. Its manifestations, nonetheless, can be hard to identify precisely. Most of its functions are not organ-specific, and there could be couple of indications or symptoms early in the disease process [(5,6)]. This ambiguity has resulted in numerous standards being utilized to define HF in epidemiological research studies. Many make use of the professional requirements developed by the Framingham Heart Study, which require 2 significant requirements, such as raised throaty venous pressure, lung rales, or a 3rd heart audio, or one significant criterion and also two minor requirements, consisting of peripheral edema, dyspnea on effort, or hepatomegaly [(7)]. Some rely upon the scientific criteria of the Cardiovascular Health Study (CHS) [(8)] or the European Society of Cardiology, [(9)] whereas others could rely on patient self-report [(2)]. The expanding prevalence of HF might show increasing occurrence, an aging population, improvements in the treatment of acute cardiovascular disease and HF, or a mix of these factors. Encouraging proof from national databases in addition to community-based mates, such as those based in Framingham and Olmsted County, [(10,11,12,13)] shows that the occurrence of HF appears to be supporting, otherwise lowering, for women, which the length of survival in patients with HF is raising. Such fads might have resulted from group shifts, changes in the occurrence of risk factors, or improvements in the availability as well as application of HF treatments [(14,15)].

Objective: This review was aimed to focuses on the main principles of heart failure, causes, consequences, mortality, symptoms, and diagnosis of HF. We attempted to also review the incidence of HF worldwide as well as the classification of HF.

2. METHODOLOGY

Comprehensive literature review was conducted using MEDLINE, CINAHL, PubMed, PsycINFO, and Cochrane Library to identify publications Up to May,2017. Method used several Keywords as; "heart failure" "Classification" "diagnosis" "Mortality". We restricted our search to only English published articles with human subjects.

3. RESULTS

- **Clinical symptoms of HF:**

The clinical symptoms of HF (**Figure 1**) consists of signs and symptoms of shortness of breath (SOB)/ dyspnea (level of sensitivity of 84% - 100%, but an uniqueness of 17% - 34%); orthopnea/SOB on lying very own (sensitivity of 22% - 50% and an uniqueness of 74% - 77%); paroxysmal nighttime dyspnea (sensitivity 39% - 41%, specificity from 80% - 84%); fatigue/weakness/lethargy (due to HF-induced circulation-related problems in skeletal muscle mass); edema, abdominal distention and appropriate hypochondrial pain (most likely because of right-sided cardiac arrest with level of sensitivity and also specificity of 23% as well as 80%, specifically) [16,17]. As a result of offsetting devices, onset of HF lack particular indications; nonetheless, late stages of HF show the following indications: tachycardia (99% uniqueness and also 7% sensitivity); pedal edema (93% specificity as well as 10% sensitivity); increased throaty venous stress (JVP) (typically > 6 centimeters; uniqueness of 92% and also level of sensitivity of 39%), irregular lung audios (crackles) (uniqueness of 78% and sensitivity of 60%); S3 gallop (uniqueness of 99% as well as sensitivity of 13%). Various other indicators, such as hepatojugular reflux and also ascites, are not located regularly in HF, yet have an uniqueness of 96% and also 97%, while a sensitivity of 24% and also 1%, specifically [18,19]. Current research has revealed the microvascular dysfunction and also succeeding reduction in O2 supply or inequality with the O2supply versus demand in HF patients. Therapeutic techniques to improve muscular tissue oxidative as well as microvascular function using exercise training, anti-inflammatory and antioxidant representatives have been recommended to be necessary to provide far better workout resistance as well as quality of life [20].



Figure1: The clinical symptoms of HF

- **Mortality of HR:**

In spite of breakthroughs in treatment and also administration, HF stays a fatal scientific syndrome. In the USA, one in eight fatalities has HF mentioned on the certification, 20% which have HF as the primary cause of death [2]. Death risk steadily boosts after a new diagnosis of HF. Based on the Framingham Heart Study, 30-day death is around 10%, 1-year death is 20 - 30%, and also 5-year mortality is 45 - 60% [4]. After a hospital stay, the prognosis aggravates. From a neighborhood research study in Worchester, MA, the 5-year death was more than 75% after the first hospitalization for HF [21]. Researches of widespread cases in Europe have somewhat a lot more beneficial estimates, with 1-year and 5-year mortality at 11% and 41%, respectively, from the Rotterdam research, [22] possibly owing to distinctions in patient selection and also interpretations of HF resulting in inclusion of milder instances. Stewart et al [23] recommended that HF was extra 'malignant' compared to cancer in a research study of over 30,000 patients hospitalized for HF, heart attack (MI), or four typical cancers in Scotland; with the exception of lung cancer, HF was connected with the worst 5-year adjusted death [23].

In a review of Medicare receivers, 30-day death from hospital admission lowered from 12.8% to 10.7% in between 1993 as well as 2006 [24]. Similar declines were seen with 5-year death, the 5-year occurrence of death from HF stayed better compared to 60% [24]. In the Scottish populace study, [12] there was a decline in 30-day death after very first a hospital stays with HF between 1986 to 2003, from 24.4% to 16.2% in men and also 20% to 16.9% in females, with differences lingering at 1-year and also 5-year follow-up. Comparable fads were seen in Canada [25] and also Olmsted County, [10] where the 5-year adjusted survival enhanced from 43% in 1979- 1984 to 52% in 1996 - 2000. However, most of these renovations remained in guys as well as more youthful adults; the 5-year adjusted death in males improved by 15% over this moment period compared with only 5% in females [10]. For the populace offered by the Kaiser Permanente system in Oregon, renovations in HF death was also seen in males however not ladies; the 5-year modified mortality boosted in guys from 82.7% to 68.8% between 1970 - 1979 and 1990 - 1994, but remained the same or even worse in females with rates from 60.8% to 64.8% [26]. The Framingham Heart Study noted similar improvement in lasting survival in both males and females (**Figure 2**) [4].



Figure 2: Age-adjusted survival after the onset of heart failure in a | men and b | women over time, from 1950 to 1999.

- **Etiology of HF:**

Although many conditions may cause HF, the predominant etiologies are myocardial ischemia and also HBP (**Table 1**) [27]. The inconsistencies in the frequency of reasons reported in the medical literary works can be described by distinctions in the study populace (from highly chosen participants in medical trials to fairly unselected topics in population-based researches, respectively), meanings (eg, consensus on a cut-off value for LVEF to specify HFPEF has actually not been reached), and amount of time (eg, the Framingham heart research study originated in 1948). It has ended up being clear

that by utilizing just noninvasive strategies, specific etiology could not constantly be identified. As an example, in the Bromley HF research study after nuclear testing and also cardiac catheterization the portion of HF with unidentified reason decreased from 42% to 10%, while the portion of patients with ischemic heart disease increased from 29% to 52% [28].

Table 1: Main causes of heart failure

• list-behavior=unordered prefix-word= mark-type=disc
• Myocardial ischemia
• HBP
• Cardiomyopathies
• Valvular heart disease
• PHT
• Congenital heart disease

Abbreviations: HBP, high blood pressure; PHT, pulmonary hypertension. See text for details.

Neurohormonal Dysregulation of HF:

The neurohormonal design of HF is mostly in charge of enhanced therapy end results in chronic systolic HF. Acutely decreased heart output or vascular underfilling leads to baroreceptor-mediated thoughtful nervous activity with consequent elevation of heart price, high blood pressure, and vasoconstriction [29]. This adjustment minimizes an acute drop in heart output, it is inevitably maladaptive as well as leads to myocardial b-receptor downregulation as well as uncoupling of contractility from normal stimuli. In chronic HF, enhanced adrenergic tone is accompanied by pathologic activation of the renin-angiotensin-aldosterone system (RAAS). Overproduction of angiotensin II boosts the adrenal glands to launch more catecholamines, which in turn promote the juxtaglomerular device in the kidney to release renin. Renin raises vascular tone and pressure overload on a heart susceptible to hemodynamic injury. Angiotensin II also boosts the adrenal secretion of aldosterone. Nonosmotic launch of vasopressin and also raised aldosterone levels lower renal excretion of water and salt, resulting in excessive preload, edema, as well as dyspnea. It is currently appreciated that neurohormonal discrepancies have straight cells results also [29]. The neurohormonal version of HF was a standard shift from the hemodynamic model. HF came to be a systemic disease responsive to pharmacologic clog of hormonal pathways. This model has been highly reliable and continues to be the foundation of chronic systolic HF treatment. Other neurohormone levels are altered in HF, including the natriuretic peptides atrial natriuretic peptide and also brain natriuretic peptide (BNP), as well as endothelin-1, yet they have actually not been proven as targets for effective treatment [30]. Analysis and also tracking of neurohormonal activation is greatly done on clinical grounds, such as heart price, high blood pressure, as well as quantity standing. If hyponatremia is existing, the standard metabolic panel is insightful. Biomarkers such as BNP and also its precursor N-terminal proBNP have been used to diagnose HF in patients with dyspnea of vague etiology [31].

- **Diagnosis Method and Classification of HR:**

For the diagnosis of HF, symptoms (typically shortness of breath at rest or throughout effort and/or tiredness), indications of fluid retention (such as pulmonary blockage and/or ankle swelling), and unbiased proof of a decrease in myocardial performance at rest (usually demonstrated in an echocardiography study) are required [32]. Inning accordance with the time from ventricular dysfunction to scientific symptoms, left ventricular ejection fraction (LVEF), and the main site of congestion, HF can be divided into different groups (Figure 1). Generally, it is a chronic condition with bouts of worsening signs that might require medical attention (decompensations). It might present acutely within just 24 hours in the type of lung edema or even cardiogenic shock. Traditionally, HF was seen to arise from the failure of the heart to pump sufficient blood into the circulation due to ventricular systolic dysfunction defined as LVEF < 40% to 50% (HF with depressed ejection portion [HFDEF] [32]. Patients with nondecreased LVEF can develop HF when greater filling pressures are required to accomplish a regular end-diastolic ventricular volume (HF with preserved ejection fraction [HFPEF]. The incident of this condition is more common in women, in the elderly, and personallies with longstanding high blood pressure (HBP) and is related to a similar prognosis to HFDEF [33,34]. And left HF refer to syndromes providing mainly with systemic or pulmonary congestion leading to jugular venous ingurgitation and ankle swelling or pulmonary edema, respectively [34].

HR can be categorized as primarily left ventricular, ideal ventricular or biventricular based upon the location of the deficit. Depending upon the time of onset, HF is categorized as chronic or acute. Scientifically, it is generally classified into 2 significant types based upon the practical status of heart: HFPEF and cardiac arrest with minimized ejection fraction (HFREF). In patients with HFPEF who are primarily females and older grownups, EF is normally more than 50%; the volume of the left-ventricular (LV) cavity is normally normal, but the LV wall is thickened and stiff; for this reason, the ratio of LV mass/end-diastolic volume is high. HFpEF is further categorized as borderline HF if the EF stays in between 41% and 49% and improved HF if EF is more than 40% [35]. In contrast, in patients with HFrEF, the LV cavity is generally dilated, and the ratio of LV mass/end-diastolic volume is either typical or lowered. At the cellular level, both cardiomyocyte size and the volume of myofibrils are higher in HFpEF than in HFrEF (35). As far as treatment and outcome are concerned, patients with HFrEF respond favorably to the standard pharmacological treatment routine and demonstrate better prognosis. On the other hand, patients with HFpEF have not been shown to react to standard medicinal treatments, except for nitrates, and therefore, have a poor prognosis, especially throughout the decompensated phase of HF [36,37]. In addition, based upon cardiac output, HF is also classified as high-output failure and low-output failure. High-output failure is an unusual disorder identified by an elevated resting heart index of greater than 2.5 - 4.0 L/min/m2 and low systemic vascular resistance. The typical reasons for high output failure are extreme anemia, vascular shunting, hyperthyroidism and vitamin B1 deficiency. This occurs as a result of ineffective blood volume and pressure, which stimulate the understanding nerve system and renin-angiotensin-aldosterone system (RAAS), causing the release of antidiuretic hormonal agent (ADH), which entirely eventually cause ventricular enhancement, unfavorable ventricular improvement and HF. Low output failure is far more typical than high-output failure and is characterized by insufficient forward heart output, especially throughout times of increased metabolic need. Left ventricular dysfunction due to large MI, ideal ventricular dysfunction due to an acute pulmonary embolus and biventricular dysfunction are important reasons for low output failure. More just recently, workout intolerance in HFpEF is proposed to be due to a decline in oxygen shipment to or impaired oxygen usage by the exercising skeletal muscles. Oxygen usage is being calculated as the arterial-venous oxygen material difference, rather than reduced cardiac output (CO [38,39]. Considering the decreased oxygen uptake kinetics in HF together with peripheral muscle function problems, workout rehabilitation seems to be a important and sensible factor in improving the inflammatory imbalance, alleviating elevated cardiac filling pressures, restoring workout capacity, quality of life and minimizing morbidity and mortality connected with HF. Workout training, mainly high strength as opposed to moderate, in HFpEF patients has actually been considerably shown to enhance rate of oxygen consumption or VO2 without affecting endothelial function [40,41].



Figure 3: Types of heart failure.

4. CONCLUSION

HF is, and will continue to be, a substantial problem on health-care systems and societies. Although age-adjusted occurrence has actually typically not been discovered to have actually increased recently, the occurrence of HF will likely continue to increase offered the significant aging of the population, enhanced survival with HF. The diagnosis of HF requires careful evaluation of each patient. Diagnostic screening is extremely influenced by the quality of the preliminary assessment and the recognition of comorbid conditions. Classifying a patient's cardiomyopathy will assist guide treatment and lend prognostic value as new and standard treatments are used.

REFERENCES

[1] Hunt SA, Abraham WT, Chin MS, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association. Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am CollCardiol. 2009;2009;53(15):e1–e90.

[2] Lloyd-Jones D, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215.

[3] McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19 (Suppl P):P9–P16.

[4] Levy D, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–1402.

[5] Davis RC, Hobbs FD, Lip GY. ABC of heart failure. History and epidemiology. BMJ. 2000;320:39–42.

[6] Remes J, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 1991;12:315–321.

[7] McKee PA, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441–1446.

[8] Di Bari M, et al. The diagnosis of heart failure in the community. Comparative validation of four sets of criteria in unselected older adults: the ICARe Dicomano Study. J Am Coll Cardiol. 2004;44:1601–1608.

[9] Schellenbaum GD, et al. Survival associated with two sets of diagnostic criteria for congestive heart failure. Am J Epidemiol. 2004;160:628–635.

[10] Roger VL, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–350.

[11] Senni M, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med. 1999;159:29–34.

[12] Jhund PS, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119:515–523.

[13] Tu JV, et al. National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994–2004. CMAJ. 2009;180:E118–E125.

[14] Redfield MM. Heart failure—an epidemic of uncertain proportions. N Engl J Med. 2002;347:1442–1444.

[15] Lee DS, et al. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med. 2004;116:581–589.

[16] Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Jr., Drazner M.H., Fonarow G.C., Geraci S.A., Horwich T., Januzzi J.L., et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013;62:e147–e239. doi: 10.1016/j.jacc.2013.05.019.

[17] Watson R.D., Gibbs C.R., Lip G.Y. ABC of heart failure. Clinical features and complications. BMJ Br. Med. J. 2000;320:236–239. doi: 10.1136/bmj.320.7229.236.

[18] Lindenfeld J., Albert N.M., Boehmer J.P., Collins S.P., Ezekowitz J.A., Givertz M.M., Katz S.D., Klapholz M., Moser D.K., Rogers J.G., et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J. Card. Fail. 2010; 16:e1–e194.

[19] Marti C.N., Georgiopoulou V.V., Kalogeropoulos A.P. Acute heart failure: Patient characteristics and pathophysiology. Curr. Heart Fail. Rep. 2013;10:427–433. doi: 10.1007/s11897-013-0151-y.

[20] Poole D.C., Hirai D.M., Copp S.W., Musch T.I. Muscle oxygen transport and utilization in heart failure: Implications for exercise (in)tolerance. Am. J. Physiol. Heart Circ. Physiol. 2012; 302:H1050–H1063. doi: 10.1152/ajpheart.00943.2011.

[21] Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term survival after heart failure: a contemporary population-based perspective. Arch Intern Med. 2007;167:490–496.

[22] Bleumink GS, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J. 2004;25:1614–1619.

[23] Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315–322.

[24] Bueno H, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA. 2010; 303:2141–2147.

[25] Tu JV, et al. National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994–2004. CMAJ. 2009; 180:E118–E125.

[26] Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970–1974 and 1990–1994. Circulation. 2006; 113:799–805.

[27] Pazos-López P, Peteiro-Vázquez J, Carcía-Campos A, García-Bueno L, de Torres JPA, Castro-Beiras A. The causes, consequences, and treatment of left or right heart failure. *Vascular Health and Risk Management*. 2011; 7:237-254. doi:10.2147/VHRM.S10669.

[28] Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001; 22(3):228–236.

[29] Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341(8): 577–85.

[30] Ky BB, French BB, Levy WC, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012;5(2):183–90.

[31] Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39(2):202–9.

[32] Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J. 2008;29(19):2388–2442.

[33] Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260–269.

[34] Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–259.

[35] Dassanayaka S., Jones S.P. Recent Developments in Heart Failure. Circ. Res. 2015; 117:e58–e63. doi: 10.1161/CIRCRESAHA.115.305765.

[36] Ohtani T., Mohammed S.F., Yamamoto K. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodeling and poor outcomes in heart failure with preserved ejection fraction. Eur. Heart J. 2012;33:1742–1749. doi: 10.1093/eurheartj/ehs135.

[37] Zamani P., Rawat D., Shiva-Kumar P., Geraci S., Bhuva R., Konda P., Doulias P.T., Ischiropoulos H., Townsend

R.R., Margulies K.B., et al. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation. 2015;131:371–380. doi: 10.1161/CIRCULATIONAHA.114.012957.

[38] Glean A.A., Ferguson S.K., Holdsworth C.T., Colburn T.D., Wright J.L., Fees A.J., Hageman K.S., Poole D.C., Musch T.I. Effects of nitrite infusion on skeletal muscle vascular control during exercise in rats with chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 2015; 309:H1354–H1360. doi: 10.1152/ajpheart.00421.2015. [

[39] Bhella P.S., Prasad A., Heinicke K., Hastings J.L., Arbab-Zadeh A., Adams-Huet B., Pacini E.L., Shibata S., Palmer M.D., Newcomer B.R., et al. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur. J. Heart Fail. 2011;13:1296–1304. doi: 10.1093/eurjhf/hfr133.

[40] Angadi S.S., Mookadam F., Lee C.D., Tucker W.J., Haykowsky M.J., Gaesser G.A. High-intensity interval training vs. moderate-intensity continuous exercise training in heart failure with preserved ejection fraction: A pilot study. J. Appl. Physiol. (1985) 2015;119:753–758. doi: 10.1152/japplphysiol.00518.2014.

[41] Paulus W.J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013;62:263–271. doi: 10.1016/j.jacc.2013.02.092.